Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2025-12-26 @ 11:56 PM
Study NCT ID:
NCT05369403
Status:
COMPLETED
Last Update Posted:
2025-03-19
First Post:
2022-05-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12-19
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-02-05
Completion Date Type:
ACTUAL
First Submit Date:
2022-05-06
First Submit QC Date:
None
Study First Post Date:
2022-05-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-01-10
Results First Submit QC Date:
None
Results First Post Date:
2025-03-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-01
Last Update Post Date:
2025-03-19
Last Update Post Date Type:
ACTUAL